Source comparison
MK-677 Mechanism Studies: Comparison of Key Clinical Trials
Healthy elderly adults (Chapman et al., 1996, JCEM) 25mg 4 weeks GH increased 55%, IGF-1 increased 46% Improved nitrogen balance, no change in cortisol Proved oral efficacy and sustained GH elevation without HPA axis disruption Young obese males (Svensson et a
This comparison does not assign a generated winner or score.
- Healthy elderly adults (Chapman et al., 1996, JCEM)
- 25mg
- 4 weeks
- GH increased 55%, IGF-1 increased 46%
- Improved nitrogen balance, no change in cortisol
- Proved oral efficacy and sustained GH elevation without HPA axis disruption
- Young obese males (Svensson et al., 1998, J Clin Endocrinol Metab)
- 8 weeks
- GH pulse amplitude increased 97%, IGF-1 up 84%
- Increased lean mass by 1.1 kg, visceral fat unchanged
- Demonstrated anabolic potential but appetite increase offset fat loss
- Elderly frail patients (Murphy et al., 1999, JBMR)
- 12 months
- Sustained IGF-1 increase of 72%
- BMD increase of 1.8% (femoral neck), improved gait speed
- Longest-duration trial. No tachyphylaxis, confirmed bone anabolic effects
- Growth hormone-deficient adults (Nass et al., 2008, JCEM)
- 6 months
- IGF-1 normalised to age-matched controls
- Body composition improved, no difference in glucose homeostasis vs placebo
- Showed clinical utility in GH deficiency without insulin resistance